Ascorbic Acid Injection Recalled Nationwide for Glass Contamination
Staska Pharmaceuticals recalled ascorbic acid injectable solution due to glass contamination. The FDA classified the recall as Class I; 4,773 vials nationwide were affected.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class I recall, which mandates a minimum score of 4. Glass contamination in an injectable product poses a material risk of serious injury through vascular or tissue damage upon administration.
Plain-English summary
Staska Pharmaceuticals, Inc. is recalling Ascorbic Acid Inj. Solution, 25,000mg/50mL (500mg/mL), 50mL single-use vials due to the presence of glass particulates in the product. This is a prescription injectable pharmaceutical.
The affected lot is #SP2400058, with an expiration date of 12/31/2024. Approximately 4,773 vials were distributed nationwide throughout the United States. The FDA has classified this as a Class I recall, indicating a serious health hazard.
Patients who may have received injections from affected vials should contact their healthcare provider. Healthcare facilities should immediately cease distribution of this lot and quarantine remaining inventory.
The recalled product
- Product
- Ascorbic Acid Inj. Solution, 25,000mg/50mL (500mg/mL), 50mL single use vial, Rx only, Staska Pharmaceuticals, 742 Evergreen Drive, Bennet, NE 68317
- Manufacturer
- Staska Pharmaceuticals, Inc.
- Hazard
- glass-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #SP2400058
- Exp 12/31/2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin 500 mg Tablets Recalled for Impurity Above Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModerateFentanyl Citrate Sterile Injection Recalled for Subpotent Drug Content
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27